EssexBio

Essex-Bio Group

简繁 EN

COMPANY NEWS

Essex Bio-Technology (1061.HK) 2025 Interim Results at a glance

2025.08.26

Related news

Essex Bio-Technology (1061.HK) 2025 Interim Results at a glance

2025-08-26

Resilient Interim Results: Essex Bio-Technology Drives Growth and Innovation, Revenue up 5.8% to HK$876.5 Million, Profit up 3.8% to HK$ 163.4 million, 16.7% Dividend Surge, Continued Innovation Momentum in Regulatory Milestones

2025-08-26

NMPA Accepted Essex’s Biologics License Application for EB12-20145P (HLX04-O) for the Treatment of Wet Age-Related Macular Degeneration.

2025-08-13

Multi-Dose Diquafosol Sodium Eye Drops Obtained Approval from NMPA for Commercialisation in China

2025-07-24

Study Primary Endpoint Met in a Phase 3 Clinical Study of Bevacizumab EB12-20145P (HLX04-O) for the Treatment of Ophthalmic Diseases

2025-04-02

Essex Bio-Technology (1061.HK) 2024 Annual Results at a glance

2025-03-26

Essex Bio-Technology Reports Stellar 2024 Annual Results：Net Profit soars 11.6% to HK$ 307.2 Million, Dividend increases 33.3% Focuses on Strengthening R&D Capabilities and Expanding Market Access

2025-03-26

Preservative-free Unit-Dose Sodium Hyaluronate Eye Drops (0.3%) Obtained Approval from NMPA for Commercialisation in China

2024-09-13

Essex Bio-Technology (1061.HK) 2024 Interim Results at a glance

2024-08-26

Essex Bio-Technology Reports 1st H 2024 Net Profit of HK$157.4 Million Poised for Future Success Underpinned by Proven Product Base and Promising Pipeline of Products

2024-08-26

Essex Bio-Technology Included in Forbes Asia's Best Under A Billion 2024

2024-08-26

Preservative-free Unit-Dose Diquafosol Sodium Eye Drops Obtained Approval from NMPA for Commercialisation in China

2024-08-14

EssexBio has climbed 13 places over the previous year in “China Pharmaceutical Industry Top 100 Series List” & Beifushu® awarded “China Pharmaceutical Brands List” for the sixth consecutive year

2024-06-27

Essex Bio-Technology (1061.HK) 2023 Annual Results at a glance

2024-03-19

Essex Bio-Technology Posts Sound 2023 Annual Financial Results: Revenue Up 29.5%, Profit Up 22.1%

2024-03-18

Change of Address of Head Office and Principal Place of Business in Hong Kong

2024-01-03

Essex Bio-Technology (1061.HK) 2023 Interim Results at a glance

2023-08-16

Essex Bio-Technology Posts Sound 2023 Interim Financial Results Revenue Up 37.1%, Profit Up 22%

2023-08-16

The phase 1/2 clinical trial of Bevacizumab for treatment of Ophthalmic Diseases completed

2023-07-26

EssexBio awarded “2022 China Pharmaceutical Industry Top 100 Series List” and “2023 China Pharmaceutical Brands List”

2023-06-30

Essex and Osteopore Entered into Exclusive Distribution Agreement for Oral Maxillofacial products in Singapore

2023-04-14

Essex and Gunze Shenzhen Entered into Exclusive Agency Agreement for PELNAC® Absorbable Dressing in Mainland China

2023-04-11

Essex Bio-Technology (1061.HK) 2022 Annual Results at a glance

2023-03-08

Essex Bio-Technology Announces 2022 Annual Financial Results, Resilience & Relevance, Growth Ready

2023-03-08

2023-02-23

Essex and Henlius signed amendment agreement for Global Co-Development and Exclusive License Agreement for treatment of age-related macular degeneration

2023-02-22

First Patient in the US Dosed in a Global Multicentre Phase 3 Clinical Study of Bevacizumab for treatment of Ophthalmic Diseases

2023-02-10

Essex Biotechnology Secures Exclusive Global Rights and Interests of SkQ1 in the field Ophthalmology from Mitotech

2022-10-13

Essex Bio-Technology (1061.HK) 2022 Interim Results at a Glance

2022-08-24

Essex Bio-Technology Announces 2022 Interim Financial Results

2022-08-23

Essex Bio-Technology Included in "Forbes Asia's Best Under A Billion 2022”

2022-08-15

EssexBio awarded “2021 China Pharmaceutical Industry Top 100 Series List” and “2022 China Pharmaceutical Brands List”

2022-07-15

Essex Bio-Technology attends the 2022 GRC-FGF Conference, with two cutting-edge scientific research accepted by GRC

2022-05-07

Essex Bio-Technology Announces Upcoming Presentation at ARVO 2022 Annual Meeting

2022-04-29

First Patient in Australia Dosed in a Global Multicentre Phase 3 Clinical Study of Bevacizumab for treatment of Ophthalmic Diseases

2022-04-19

First Patient Dosed in a Global Multi-Centre Phase 3 Clinical Study of Bevacizumab EB12-20145P (HLX04-O) for treatment of Ophthalmic Diseases in the EU

2022-04-08

Essex Bio-Technology Announces 2021 Financial Results Achieves an increase of 58% in Profit-After-Tax to HK$346.0 million and Turnover Growth of 67.4% to HK$1,637.7 million

2022-03-22

Essex Bio-Technology Wins "Best Investment Value Award for Listed Companies" under China Securities Golden Bauhinia Awards Gains Wide Recognition from Capital Market for Comprehensive Strength and Investment Value

2021-12-20

First Patient First Visit Completed in the PRC in a Phase 3 Clinical Trial of Bevacizumab EB12-20145P (HLX04-O)

2021-11-10

Essex Bio-Technology to Present at the 5th China Bio-Pharm Partnering Forum (Bio-Pharm 2021)

2021-10-27

Essex Bio-Technology Reports First Half 2021 Financial Results

2021-08-12

Essex Bio-Technology Listed on Two Authoritative Lists

2021-07-25

First Patient First Visit Completed in the PRC in Clinical Trial of Bevacizumab EB12-20145P (HLX04-O)

2021-07-19

Essex Bio-Technology Announces Upcoming Presentation at ARVO 2021 Annual Meeting

2021-04-30

Application for Clinical Trial of Bevacizumab Has Been Approved for the Treatment of wAMD in Latvia

2021-04-20

Preservative-free Unit-dose Moxifloxacin Hydrochloride Eye Drops Obtained Approval from NMPA for Commercialisation in China

2021-04-07

Essex-Biotechnology Announces Bevacizumab Has Received IND Approval from US FDA for the Treatment of wAMD

2021-03-19

Essex Bio-Technology Announces 2020 Financial Results Sales of HK$654m & PAT of HK$170m recorded in 2nd Half

2021-03-12

Essex Bio-Technology and Mitotech announce positive outcome of VISTA-2 Phase 3 clinical study in Dry Eye Disease

2021-02-24

Essex-Biotechnology Announces Bevacizumab for wAMD Has Received Clinical Trial Approval in Australia

2021-01-29

Essex Bio-Technology Included in Forbes Asia's Best Under A Billion 2020

2020-11-23

Essex and Henlius Entered into a Global Co-Development and Exclusive License Agreement to Jointly Develop Bevacizumab for Treatment of Ophthalmic Diseases

2020-10-15

Essex Bio-Technology and Mitotech Complete Enrollment in VISTA-2 – a Pivotal Phase 3 Clinical Study of SkQ1 for Dry Eye Disease

2020-08-25

Essex Bio-Technology Reports First Half 2020 Financial Results

2020-08-18

Essex Bio-Technology Enters into Global Out-licence Agreement with Kelun-Biotech

2020-08-10

Essex Bio-Technology Joins X-ZELL Seed+ Investment Round

2020-04-30

FY 2019 Profit-After-Tax Up 30.9% to HK$302.5 million,was up 36.5% in RMB denomination

2020-03-17

Preservative-free Single-dose rb-bFGF Eye Drops (Single-Dose Beifushu Eye Drops) Obtained Approval from NMPA for Commercialisation in China

2019-12-27

Essex Bio-Technology and Mitotech Announce First Patient First Visit in U.S. FDA Second Phase 3 Clinical Trial of SkQ1

2019-12-12

Admission of Product to the PRC National Drug List for Reimbursement, Beifuxin Newly Listed and the Other Three Products Remain on the List

2019-08-21

Essex Biotech's mid-2019 net profit increased by 31% year-on-year to HK$129 million

2019-08-12

Essex Bio-Technology and Antikor Biopharma Forge Strategic Alliance in FDC for Cancer Treatment

2019-08-02

Essex Bio-Technology and Mitotech Announce Topline Results from VISTA-1, Phase 3 Clinical Trial in U.S. FDA of a First-In-Class Drug for Dry Eye Disea

2019-07-19

Essex Bio-Technology Included by MSCI as A Constituent of The MSCI China Small Cap Index

2019-05-15

Essex Bio-Technology Announces Upcoming Joint Presentation with Mitotech and Ora at ARVO 2019 Annual Meeting

2019-04-29

FY18 Turnover & Net Profit grew 30.8% and 38.1% to HK$1,176.5 million & HK$ 231.1 million, respectively

2019-03-12

The cellular growth factor project of Essex Bio-Technology Limited was honoured with the second prize of National Scientific and Technology Progress Award

2019-01-10

Essex Bio-technology Entered into Convertible Notes Purchase Agreement and License Agreement with DB Therapeutics

2018-10-30

Essex Bio-Technology Announces First Patient First Visit in U.S. FDA Phase 3 Clinical Trial of SkQ1 Occurred on 27 October 2018

2018-10-29

Preservative-free Single-dose Sodium Hyaluronate Eye Drops Obtained Approval from SDA for Commercilisation in China

2018-08-22

Group Turnover and Profit in the First Half of 2018 Increased 28.3%

2018-08-10

Essex Bio-Technology Investing in Chengdu Shanggong Medical Technology Co.,Ltd., A Data Analytics Company for Diabetic Retinopathy Diagnosis

2018-07-24

Essex Bio-Technology Enters into Global Co-Development Agreement with Mitotech to Fund Phase 3 Clinical Trial in U.S. FDA of a First-In-Class Drug for Dry Eye Disease

2018-07-18

Zhuhai Essex Bio-Pharmaceutical Obtained a GMP Certificate for Preservative-Free Single-Dose Tobramycin Eye Drops

2018-04-12

Essex Bio-Technology appoints Dr. Xue Qi as Chief Scientific Officer for its R&D Centre in USA

2018-04-10

Group Profit Recorded Growth of 22.8% in 2017

2018-03-16

Change of Company Logo Represents a Transformation for Essex Bio-Technology Pioneering Global Regenerative Science & Technology

2018-03-06

Essex Bio-Technology announces investment in MeiraGTx, a biotech company developing novel gene therapy treatments

2018-02-26

This website uses cookies to improve your overall experience. With your continued use, you are agreeing to accept our use of cookies.

ACCEPT